Table 1.
Cohorts utilized to characterize relative prevalence of RAS mutations in colorectal cancer and their characteristics.
| Cohort | MDA CMS 46 (32) | Mayo | MDA T200 (33) | CARIS | Project Genie (34) | TCGA (35) | NHS & HPFS (36) | cfDNA (37) |
|---|---|---|---|---|---|---|---|---|
| Patients | 1877 | 1078 | 207 | 2200 | 2081 | 228 | 619 | 1397 |
| RAS Coverage | Hot spot | Hot spot | All exons | All exons | Mixed | All exons | All exons | All exons |
| Assay Type | 46 Gene Multiplex | 46 Gene Multiplex | 201 Gene; Capture Based | 592 Gene; Hybrid Capture Based | Mixed | Exome | Exome | 54 to 73 Gene cfDNA |
| Assay Depth | ≥250X | ≥250X | Median 906X (tumor) | >750X | Varied by Platform | >20X for 80% of exons | Median 88X (tumor) | 8000X |
| Tumor Cellularity | >20% | >20% | >20% | >20% | >10% | ≥60% | Average 45% | n/a |
| Stage of Patients | Stage IV | Stage IV | Stage IV | Mostly Stage IV | Mostly Stage IV | Stage I-IV | Stage I-IV | Mostly Stage IV |
| Publicly Available | No | No | No | No | Yes | Yes | Yes | No |